India’s D2C beauty and wellness ecosystem continues to witness rapid evolution, and Honasa Consumer has taken another major step in its growth journey with the acquisition of a 58% stake in nutraceuticals company Fluence Pharma. The transaction, valued at an enterprise value of approximately ₹135 crore, marks Honasa’s entry into the fast-growing nutraceuticals category and reinforces its ambition to build a broader science-led health, wellness, and beauty portfolio.
The acquisition is one of the notable developments in D2C acquisitions 2025 and highlights the increasing convergence of beauty, wellness, and preventive healthcare within the Direct-to-consumer India ecosystem. As consumers increasingly seek holistic health solutions, many leading D2C brands India are expanding beyond their core categories to capture new opportunities in adjacent markets.
Under the agreement, Honasa Consumer will acquire 58% of Fluence Pharma immediately and plans to purchase the remaining 42% stake in two phases over the next five to seven years. The company will also establish a wholly owned subsidiary, Honasa Health, dedicated to building a consumer-focused nutraceuticals business and accelerating growth in the wellness category.
Founded in 2012 by Amit Bhusari and Dr. Rajendra Singh Rajput, Fluence Pharma has built a strong reputation in the dermatology-led nutrition space. The company operates brands including Hair Fact, Skin Fact, and Pro Fact and is known for its proprietary Cyclical Nutrition Therapy (CNT) platform. Over the years, Fluence Pharma has developed a network of more than 3,000 dermatologists across India, creating a strong foundation for growth and consumer trust.
The acquisition aligns closely with evolving D2C consumer behavior India, where consumers increasingly view beauty and wellness as interconnected categories. Demand for “inside-out” beauty solutions, nutritional supplementation, and science-backed wellness products has accelerated significantly, creating substantial opportunities for D2C wellness startups and established consumer brands alike.
India’s nutraceuticals market is currently estimated to be worth more than ₹16,000 crore and continues to attract significant investor attention. As D2C market trends 2025 increasingly focus on wellness, preventive healthcare, and personalized nutrition, the category is emerging as one of the most attractive growth segments within the broader D2C ecosystem India.
Fluence Pharma brings strong business fundamentals to the partnership. According to company disclosures, the business generated approximately ₹40 crore in revenue during FY26 while maintaining EBITDA margins above 20%. More than 70% of its revenue currently comes from hair-health-focused products, highlighting its strong positioning in one of the fastest-growing wellness categories.
For Honasa Consumer, the acquisition provides an opportunity to combine Fluence Pharma’s scientific expertise, practitioner network, and product innovation capabilities with its own strengths in brand building, digital marketing, consumer engagement, and omnichannel D2C strategy. This combination has the potential to accelerate product innovation, improve distribution, and unlock new growth opportunities across multiple wellness categories.
The deal also reflects a broader consolidation trend shaping Indian D2C updates. Over the past few years, India’s D2C beauty and wellness sector has witnessed a growing number of acquisitions as larger consumer companies seek to strengthen their portfolios through science-led and digital-first brands. The increasing pace of consolidation demonstrates the maturity of India’s D2C business landscape and growing investor confidence in scalable consumer brands.
As D2C industry news continues to highlight expansion, acquisitions, and category diversification, Honasa’s investment in Fluence Pharma represents a strategic move into one of the most promising segments of the consumer health market. With strong category tailwinds, an established practitioner network, profitable operations, and growing consumer demand for wellness solutions, Fluence Pharma appears well-positioned to contribute meaningfully to Honasa’s next phase of growth while strengthening its leadership across India’s rapidly evolving beauty and wellness ecosystem.